According to the National Organizations of Rare Disorders, hemophilia A is a common X-linked recessive disorder and the second most common inherited clotting factor deficiency after von Willebrand disease. According to the National Library of Medicine (NLM), ~30,000–33,000 males were affected by hemophilia in the US in 2020. In the US, ~1 in 5,000 newborn males suffers from hemophilia A. According to National Organization for Rare Disorders, in 2022, immune thrombocytopenia (ITP), an autoimmune bleeding disorder, affects ~66 adults per 1 million in the US. Moreover, in the country, the incidence of ITP in adults is ~3.3 per 100,000/year, while the prevalence is 9.5 per 100,000. Furthermore, according to the US Department of Health & Human Services, in 2020, ~100,000 Americans had sickle cell disease (SCD), the most inherited blood disorder. Furthermore, by 2050, the number of SCD cases is expected to grow by ~30%. Hence, Plasma is a liquid portion of blood containing WBC and platelets. Blood plasma derivatives play a major role in stopping bleeding after an injury. Thus, the increasing prevalence of blood disorders across the world is one of the major driving factors promoting the growth of the blood plasma derivatives market growth.
The North America blood plasma derivatives market has been segmented into the US, Canada, and Mexico. US is expected to account for the largest market share. The prevalence of severe diseases, including hemophilia and immune deficiency disorders, is a main factor driving the market for blood plasma derivatives. According to the Centers for Disease Control and Prevention (CDC) data, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. The exact number of people living with hemophilia in the US is unknown. Based on a recent study that used data collected on patients receiving care in federally funded hemophilia treatment centers during the period 2012-2018, as many as 33,000 males in the US are living with the disorder.
Furthermore, as per World Health Organization (WHO), out of 250,000 individuals diagnosed with PID (primary immune deficiencies) in the US in 2017, roughly 125,000 get month-to-month mixtures of immunoglobulins. It is assessed that more than 300,000 patients get monthly-to-month immunoglobulins implantations for PID. The rise in chronic conditions and increasing demand for immunoglobulin drive the development of the blood plasma derivatives market.
The North America blood plasma derivatives market is segmented into type, application, end user, and country.
The North America blood plasma derivatives market, by type, is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The immunoglobulins segment held a larger market share in 2022.
Based on application, the North America blood plasma derivatives market is divided into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The immunodeficiency diseases applications segment held the largest share of the market in 2022.
The blood plasma derivatives market, by end user, is segmented into hospitals, diagnostic laboratories, clinics, and other end users. The hospitals segment held the largest share of the market in 2022.
Based on country, the North America blood plasma derivatives market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.
Grifols SA; SK Plasma Co Ltd; Octapharma AG; Monobind Inc.; Intas Pharmaceuticals Ltd; Takeda Pharmaceutical Co Ltd; CSL Behring LLC; LFB SA; and Kedrion SpA are the leading companies operating in the North America blood plasma derivatives market.